CSF MicroRNAs Reveal Impairment of Angiogenesis and Autophagy in Parkinson Disease
Alan J Fowler, Jaeil Ahn, Michaeline Hebron, Timothy Chiu, Reem Ayoub, Sanjana Mulki, Habtom Ressom, Yasar Torres-Yaghi, Barbara Wilmarth, Fernando L Pagan, Charbel Moussa, Alan J Fowler, Jaeil Ahn, Michaeline Hebron, Timothy Chiu, Reem Ayoub, Sanjana Mulki, Habtom Ressom, Yasar Torres-Yaghi, Barbara Wilmarth, Fernando L Pagan, Charbel Moussa
Abstract
Background and objectives: We assessed longitudinal changes in CSF microRNAs (miRNAs) in patients with moderately severe Parkinson disease.
Methods: We used next-generation whole-genome miRNA sequencing to determine CSF miRNA expression in 75 patients with Parkinson disease after single random ascending doses of nilotinib and longitudinal miRNA expression after daily nilotinib, 150 and 300 mg, vs placebo for 1 year.
Results: Significant changes in the expression of miRNAs that control genes and pathways that regulate angiogenesis, autophagy, and the blood-brain-barrier components, primarily collagen, were observed over 1 year, suggesting impairment of these pathways in Parkinson progression in these patients. Different miRNAs that indicate activation of genes associated with autophagy flux and clearance and angiogenesis were significantly altered in the nilotinib, 300 mg vs 150 mg, or placebo group, and these changes correlated with clinical outcomes. No changes were observed in miRNAs after a single dose of nilotinib vs placebo.
Discussion: This study suggests vascular and autophagy defects in Parkinson progression. Nilotinib, 300 mg, reverses these effects via alteration of miRNA expression, suggesting epigenomic changes that may underlie long-term disease-modifying effects.
Trial registration information: Clinical trial registration number: NCT02954978.
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Figures
References
- Fowler AJ, Hebron M, Balaraman K, et al. . Discoidin Domain Receptor 1 is a therapeutic target for neurodegenerative diseases. Hum Mol Genet. 2020;29(17):2882-2898.
- Lonskaya I, Hebron ML, Algarzae NK, Desforges N, Moussa CE. Decreased parkin solubility is associated with impairment of autophagy in the nigrostriatum of sporadic Parkinson's disease. Neuroscience. 2013;232:90-105.
- Lonskaya I, Shekoyan AR, Hebron ML, Desforges N, Algarzae NK, Moussa CE. Diminished parkin solubility and co-localization with intraneuronal amyloid-beta are associated with autophagic defects in Alzheimer's disease. J Alzheimers Dis. 2013;33(1):231-247.
- Hebron M, Peyton M, Liu X, et al. . Discoidin domain receptor inhibition reduces neuropathology and attenuates inflammation in neurodegeneration models. J Neuroimmunol. 2017;311(1):1-9.
- Vogel W, Brakebusch C, Fassler R, Alves F, Ruggiero F, Pawson T. Discoidin domain receptor 1 is activated independently of beta(1) integrin. J Biol Chem. 2000;275(8):5779-5784.
- Zhu M, Xing D, Lu Z, et al. . DDR1 may play a key role in destruction of the blood-brain barrier after cerebral ischemia-reperfusion. Neurosci Res. 2015;96:14-19.
- Fowler AJ, Hebron M, Missner AA, et al. . Multikinase Abl/DDR/Src inhibition produces optimal effects for tyrosine kinase inhibition in neurodegeneration. Drugs R D 2019;19(2):149-166.
- Hebron ML, Lonskaya I, Moussa CE. Tyrosine kinase inhibition facilitates autophagic SNCA/alpha-synuclein clearance. Autophagy. 2013;9(8):1249-1250.
- Hebron ML, Lonskaya I, Moussa CE. Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of alpha-synuclein in Parkinson's disease models. Hum Mol Genet. 2013;22(16):3315-3328.
- Lonskaya I, Desforges NM, Hebron ML, Moussa CE. Ubiquitination increases parkin activity to promote autophagic alpha-synuclein clearance. Plos One. 2013;8(12):e83914.
- Lonskaya I, Hebron M, Desforges NM, Franjie A, Moussa CE. Tyrosine kinase inhibition increases functional parkin-Beclin-1 interaction and enhances amyloid clearance and cognitive performance. EMBO Mol Med. 2013;5(8):1247-1262.
- Lonskaya I, Hebron M, Desforges NM, Schachter JB, Moussa CE. Nilotinib-induced autophagic changes increase endogenous parkin level and ubiquitination, leading to amyloid clearance. J Mol Med. 2014;92(4):373-386.
- Hebron ML, Javidnia M, Moussa CE. Tau clearance improves astrocytic function and brain glutamate-glutamine cycle. J Neurol Sci. 2018;391:90-99.
- Pagan F, Hebron M, Valadez EH, et al. . Nilotinib effects in Parkinson's disease and dementia with Lewy bodies. J Parkinsons Dis. 2016;6(3):503-517.
- Pagan FL, Hebron ML, Wilmarth B, et al. . Nilotinib effects on safety, tolerability, and potential biomarkers in Parkinson disease: a phase 2 randomized clinical trial. JAMA Neurol. 2019;77(3):309-317.
- Pagan FL, Hebron ML, Wilmarth B, et al. . Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson's disease. Pharmacol Res Perspect. 2019;7(2):e00470.
- Deremer DL, Ustun C, Natarajan K. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clin Ther. 2008;30(11):1956-1975.
- Jeitany M, Leroy C, Tosti P, et al. . Inhibition of DDR1-BCR signalling by nilotinib as a new therapeutic strategy for metastatic colorectal cancer. EMBO Mol Med. 2018;10(4):e7918.
- Day E, Waters B, Spiegel K, et al. . Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. Eur J Pharmacol. 2008;599(1-3):44-53.
- Manley PW, Drueckes P, Fendrich G, et al. . Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta. 2010;1804(3):445-453.
- Pagan FL, Wilmarth B, Torres-Yaghi Y, et al. . Long-term safety and clinical effects of nilotinib in Parkinson's disease. Mov Disord. 2021;36(3):740-749.
- Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.
- Tarazona S, Furio-Tari P, Turra D, et al. . Data quality aware analysis of differential expression in RNA-seq with NOISeq R/Bioc package. Nucleic Acids Res. 2015;43(21):e140.
- Mi H, Muruganujan A, Huang X, et al. . Protocol Update for large-scale genome and gene function analysis with the PANTHER classification system (v.14.0). Nat Protoc. 2019;14(3):703-721.
- Orr M, Liu P. Sample size estimation while controlling false discovery rate for microarray experiments using ssize.fdr package. R J. 2009;1:47-53.
- Chou CH, Shrestha S, Yang CD, et al. . miRTarBase update 2018: a resource for experimentally validated microRNA-target interactions. Nucleic Acids Res. 2018;46(D1):D296-D302.
- Klionsky DJ, Abdelmohsen K, Abe A, et al. . Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016;12(1):1-222.
- Fowler AJ, Moussa CE. Activating autophagy as a therapeutic strategy for Parkinson's disease. CNS Drugs. 2018;32(1):1-11.
- Eskelinen EL. Roles of LAMP-1 and LAMP-2 in lysosome biogenesis and autophagy. Mol Aspects Med. 2006;27(5-6):495-502.
- Saftig P, Beertsen W, Eskelinen EL. LAMP-2: a control step for phagosome and autophagosome maturation. Autophagy. 2008;4(4):510-512.
- Liu X, Hebron M, Shi W, Lonskaya I, Moussa CE. Ubiquitin specific protease-13 independently regulates parkin ubiquitination and alpha-synuclein clearance in alpha-synucleinopathies. Hum Mol Genet. 2019;28(4):548-560.
- Ngai D, Lino M, Rothenberg KE, Simmons CA, Fernandez-Gonzalez R, Bendeck MP. DDR1 (discoidin domain receptor-1)-RhoA (ras homolog family member A) axis senses matrix stiffness to promote vascular calcification. Arterioscler Thromb Vasc Biol. 2020;40(7):1763-1776.
- Jing H, Song J, Zheng J. Discoidin domain receptor 1: new star in cancer-targeted therapy and its complex role in breast carcinoma. Oncol Lett. 2018;15(3):3403-3408.
- Munoz DG, Woulfe JM. Angiogenesis: a new paradigm for Parkinson disease with practical and pathogenic implications. Neurology. 2015;85(21):1826-1827.
- Vogel W, Gish GD, Alves F, Pawson T. The discoidin domain receptor tyrosine kinases are activated by collagen. Mol Cel. 1997;1(1):13-23.
- Shrivastava A, Radziejewski C, Campbell E, et al. . An orphan receptor tyrosine kinase family whose members serve as nonintegrin collagen receptors. Mol Cel. 1997;1(1):25-34.
- Ratzka A, Baron O, Grothe C. FGF-2 deficiency does not influence FGF ligand and receptor expression during development of the nigrostriatal system. PLoS One. 2011;6(8):e23564.
- Timmer M, Cesnulevicius K, Winkler C, et al. . Fibroblast growth factor (FGF)-2 and FGF receptor 3 are required for the development of the substantia nigra, and FGF-2 plays a crucial role for the rescue of dopaminergic neurons after 6-hydroxydopamine lesion. J Neurosci. 2007;27(3):459-471.
- Barcia C, Bautista V, Sanchez-Bahillo A, et al. . Changes in vascularization in substantia nigra pars compacta of monkeys rendered parkinsonian. J Neural Transm (Vienna). 2005;112(9):1237-1248.
- Turner RS, Hebron ML, Lawler A, et al. . Nilotinib effects on safety, tolerability, and biomarkers in Alzheimer's disease. Ann Neurol. 2020;88(1):183-194.
- Desai Bradaric B, Patel A, Schneider JA, Carvey PM, Hendey B. Evidence for angiogenesis in Parkinson's disease, incidental Lewy body disease, and progressive supranuclear palsy. J Neural Transm (Vienna). 2012;119(1):59-71.
- Franco C, Hou G, Ahmad PJ, et al. . Discoidin domain receptor 1 (ddr1) deletion decreases atherosclerosis by accelerating matrix accumulation and reducing inflammation in low-density lipoprotein receptor-deficient mice. Circ Res. 2008;102(10):1202-1211.
- Janelidze S, Lindqvist D, Francardo V, et al. . Increased CSF biomarkers of angiogenesis in Parkinson disease. Neurology. 2015;85(21):1834-1842.
- Raz L, Knoefel J, Bhaskar K. The neuropathology and cerebrovascular mechanisms of dementia. J Cereb Blood Flow Metab. 2016;36(1):172-186.
- Rosenberg GA. Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol. 2009;8(2):205-216.
- Oh S, Seo M, Choi JS, Joo CK, Lee SK. MiR-199a/b-5p inhibits lymphangiogenesis by targeting discoidin domain receptor 1 in corneal injury. Mol Cell. 2018;41(2):93-102.
- Stamatovic SM, Keep RF, Andjelkovic AV. Brain endothelial cell-cell junctions: how to “open” the blood brain barrier. Curr Neuropharmacol. 2008;6(3):179-192.
- Leitinger B, Saltel F. Discoidin domain receptors: multitaskers for physiological and pathological processes. Cell Adh Migr. 2018;12(4):398-399.
- Roberts ME, Magowan L, Hall IP, Johnson SR. Discoidin domain receptor 1 regulates bronchial epithelial repair and matrix metalloproteinase production. Eur Respir J. 2011;37(6):1482-1493.
- Dorison A, Dussaule JC, Chatziantoniou C. The role of discoidin domain receptor 1 in inflammation, fibrosis and renal disease. Nephron. 2017;137(3):212-220.
Source: PubMed